Cerebrospinal fluid ratio of phosphorylated tau protein and beta amyloid predicts amyloid PET positivity

Česká verzia

Authors: J. Cerman ^1,2; J. Laczó ^1,2; M. Vyhnálek ^1,2; J. Malinovská ¹; J. Hanzalová ¹; J. Hort ^1,2
Authors place of work: Neurologická klinika 2. LF UK, a FN Motol, Praha ¹; Mezinárodní centrum klinického, výzkumu, FN u sv. Anny v Brně ²
Published in the journal: Cesk Slov Neurol N 2020; 83(2): 173-179
Category: Original Paper
doi: https://doi.org/10.14735/amcsnn2020173

Současná diagnostická kritéria Alzheimerovy nemoci zdůrazňují vedle klinické diagnózy také vyšetření metabolických biomarkerů. V ČR je dostupné vyšetření pomocí amyloidové PET a vyšetření biomarkerů v likvoru (hladiny beta amyloidu Aβ 1-42, celkového tau a fosforylovaného tau 181). Cílem této studie bylo zhodnotit konkordanci amyloidové PET a biomarkerů v likvoru v klinických podmínkách a navrhnout způsob interpretace výsledků likvoru ke zlepšení predikce výsledku amyloidové PET především u rozporných případů.

Summary

Aim: Current diagnostic criteria for Alzheimer’s disease shift the focus from clinical findings to metabolic biomarkers. Most widely used metabolic biomarkers in the Czech Republic are cerebrospinal fluid levels of beta amyloid 1-42, total tau, and phosphorylated tau 181, as well as amyloid PET. Our aim was to investigate the concordance of amyloid PET and cerebrospinal fluid biomarkers in clinical settings and propose a way of interpreting cerebrospinal fluid biomarker results in order to better predict the amyloid PET status in contradictory cases.

Methods: A total of 103 patients underwent neuropsychological assessment, brain MRI, visually evaluated flutemetamol amyloid PET and examination of biomarkers in the cerebrospinal fluid. Concordance of amyloid PET and cerebrospinal fluid biomarkers was compared and subsequent optimal cut-off for the beta amyloid 1-42 and phosphorylated tau protein ratio was calculated.

Results: Concordance between amyloid PET and beta amyloid 1-42 was 79%, followed by phosphorylated tau protein (72%). In 40% of cases, the results of cerebrospinal fluid biomarkers was contradictory. Beta amyloid 1-42 and phosphorylated tau protein ratio was found to best discriminate between amyloid PET positive and negative patients (AUC = 0.938, 95% CI = 0.890–0.986; P < 0.001). Ratio of 9.47 provided 91.0% sensitivity and 91.3% specificity.

Conclusion: Both methods show good diagnostic concordance. In case of contradictory cerebrospinal fluid biomarkers, we encourage using the beta amyloid 1-42 and phosphorylated tau protein ratio.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Keywords:

Alzheimer‘s disease – biomarkers – amyloid PET – cerebrospinal fluid – flutemetamol – beta amyloid Aβ 1-42 – tau protein

Zdroje

1. McKhann GM, Knopman DS, Chertkow H et al. The diag-nosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7 (3): 263–269. doi: 10.1016/j.jalz.2011.03.005.

2. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7 (3): 270–279. doi: 10.1016/j.jalz.2011.03.008.

3. Ressner P, Hort J, Rusina R. Doporučené postupy pro diagnostiku Alzheimerovy nemoci a dalších onemoc-nění spojených s demencí. Cesk Slov Neurol N 2008; 71/104 (4): 494–501.

4. Hort J, Glosová L, Vyhnálek M et al. Tau protein a beta amyloid v likvoru u Alzheimerovy choroby. Cesk Slov Neurol N 2007; 70/103 (1): 30–36.

5. Nelson PT, Dickson DW, Trojanowski JQ et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 2019; 142 (6): 1503–1527. doi: 10.1093/brain/awz099.

6. Jack CR, Knopman DS, Jagust WJ et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12 (2): 207–216. doi: 10.1016/S1474-4422 (12) 70291-0.

7. Jack CR, Bennett DA, Blennow K et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14 (4): 535–562. doi: 10.1016/j.jalz.2018.02.018.

8. Beach TG, Monsell SE, Phillips LE et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012; 71 (4): 266–273. doi: 10.1097/NEN.0b013e31824b211b.

9. Salloway S, Sperling R, Fox NC et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370 (4): 322–333. doi: 10.1056/NEJMoa1304839.

10. Degenhardt EK, Witte MM, Case MG et al. Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics 2016; 57 (2): 208–216. doi: 10.1016/j.psym.2015.12.002.

11. SÚKL. Opatření obecné povahy. [online]. Dostupné z URL: http: //www.sukl.cz/file/88095_1_1.

12. Vos SJB, Visser PJ, Verhey F et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS One 2014; 9 (6): e100784. doi: 10.1371/journal.pone.0100784.

13. Mattsson N, Andreasson U, Persson S et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7 (4): 386–395. doi: 10.1016/j.jalz.2011.05.2243.

14. Verwey NA, van der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 2009; 46 (Pt 3): 235–240. doi: 10.1258/ acb.2009.008232.

15. Salloway S, Gamez JE, Singh U et al. Performance of [18F] flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease. Alzheimers Dement (Amst.) 2017; 9: 25–34. doi: 10.1016/j.dadm.2017.06. 001.

16. Curtis C, Gamez JE, Singh U et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 2015; 72 (3): 287–294. doi: 10.1001/jamaneurol.2014.4144.

17. Thurfjell L, Lilja J, Lundqvist R et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 2014; 55 (10): 1623–1628. doi: 10.2967/jnumed.114.142109.

18. Belohlavek O, Jaruskova M, Skopalova M et al. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging 2019; 46 (2): 297–303. doi: 10.1007/s00259-018-4140-y.

19. Blennow K, Mattsson N, Schöll M et al. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015; 36 (5): 297–309. doi: 10.1016/j.tips.2015.03.002.

20. Leuzy A, Carter SF, Chiotis K et al. Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2015; 45 (4): 1077–1088. doi: 10.3233/JAD-142952.

21. Zwan MD, van Harten A, Ossenkoppele R et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis 2014; 41 (3): 801–807. doi: 10.3233/JAD-132561.

22. Hansson O, Seibyl J, Stomrud E et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 2018; 14 (11): 1470–1481. doi: 10.1016/j.jalz.2018.01.010.

23. Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement 2012; 8 (1): 65–73. doi: 10.1016/j.jalz.2011.07.004.

24. Bartoš A, Čechová L, Švarcová J et al. Likvorový triplet (tau proteiny a beta-amyloid) v diagnostice Alzheimerovy-Fischerovy nemoci. Cesk Slov Neurol N 2012; 75/108 (5): 587–594.

25. Bartoš A, Smětáková M, Nosková L et al. Možnosti stanovení likvorového tripletu tau proteinů a β-amyloidu 42 metodami ELISA a orientační normativní vodítka Cesk Slov Neurol N 2019; 82/115 (5): 533–540. doi: 10.14735/amcsnn2019533.

26. Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther 2017; 6 (Suppl 1): 15–24. doi: 10.1007/s40120-017-0073-9.

27. Schauer SP, Mylott WR, Yuan M et al. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays. Alzheimers Res Ther 2018; 10 (1): 118. doi: 10.1186/s13195-018-0445-0.

28. Teunissen CE, Petzold A, Bennett JL et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73 (22): 1914–1922. doi: 10.1212/WNL.0b013e3181c47cc2.

29. Jack CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010; 9 (1): 119–128. doi: 10.1016/S1474-4422 (09) 70299-6.

30. Blennow K, Wallin A, Häger O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993; 88 (3): 221–223. doi: 10.1111/j.1600-0404.1993.tb04221.x.

31. Duits FH, Martinez-Lage P, Paquet C et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 2016; 12 (2): 154–163. doi: 10.1016/j.jalz.2015.08.003.

32. Lucey BP, Fagan AM, Holtzman DM et al. Diurnal oscillation of CSF Aβ and other AD biomarkers. Mol Neurodegener 2017; 12 (1): 36. doi: 10.1186/s13024-017-0161-4.

33. Woodward M, MacKenzie IR, Hsiung GY et al. Multiple brain pathologies in dementia are common. Eur Geriatr Med 2010; 1 (5): 259–265. doi: 10.1016/j.eurger.2010.07.012.

34. Kalvach P, Kupka K, Vogner M. Je amyloid podstatný pro senilní demenci? Cesk Slov Neurol N 2018; 81/114 (2): 164–170. doi: 10.14735/amcsnn2018csnn.eu1.